Margriet Kwint

Chapter 3 66 15. Griffioen GH, Toguri D, Dahele M, et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (nsclc): Patient outcomes and prognostic factors. Lung cancer 2013;82:95-102. 16. Hasselle MD, Haraf DJ, Rusthoven KE, et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7:376-381. 17. Hendriks LE, Derks JL, Postmus PE, et al. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage iv non-small cell lung cancer: Results from a population-based study. European journal of cancer 2015;51:2534-2544. 18. Khan AJ, Mehta PS, Zusag TW, et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (nsclc). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2006;81:163-167. 19. Lopez Guerra JL, Gomez D, Zhuang Y, et al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. International journal of radiation oncology, biology, physics 2012;84:e61-67. 20. Palma DA, Haasbeek CJ, Rodrigues GB, et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (sabr-comet): Study protocol for a randomized phase ii trial. BMC cancer 2012;12:305. 21. Parlak C, Mertsoylu H, Guler OC, et al. Definitive chemoradiation therapy following surgical resection or radiosurgery plus whole-brain radiation therapy in non-small cell lung cancer patients with synchronous solitary brain metastasis: A curative approach. International journal of radiation oncology, biology, physics 2014;88:885-891. 22. Pfannschmidt J, Dienemann H. Surgical treatment of oligometastatic non-small cell lung cancer. Lung cancer 2010;69:251-258. 23. Plones T, Osei-Agyemang T, Krohn A, et al. Surgical treatment of extrapulmonary oligometastatic non-small cell lung cancer. The Indian journal of surgery 2015;77:216-220. 24. Rusthoven CG, Yeh N, Gaspar LE. Radiation therapy for oligometastatic non-small cell lung cancer: Theory and practice. Cancer journal 2015;21:404-412. 25. Salama JK, Schild SE. Radiation therapy for oligometastatic non-small cell lung cancer. Cancer metastasis reviews 2015;34:183-193. 26. Sheu T, Heymach JV, Swisher SG, et al. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. International journal of radiation oncology, biology, physics 2014;90:850-857. 27. Xanthopoulos EP, Handorf E, Simone CB, 2nd, et al. Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study. Practical radiation oncology 2015;5:e355-363. 28. Treasure T. Oligometastatic cancer: An entity, a useful concept, or a therapeutic opportunity? Journal of the Royal Society of Medicine 2012;105:242-246. 29. Uyterlinde W, Belderbos J, Baas C, et al. Prediction of acute toxicity grade >/= 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose cisplatin. Clinical lung cancer 2013;14:541-548.